USD10
REGN Shares
About Regeneron PharmaceuticalsRegeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
USD10
REGN Shares
About Regeneron PharmaceuticalsRegeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 24 at 1:30 PM GMT+0
MARKET CAP
$77.87B
OPEN PRICE
Not enough data
LOW (1Y)
$476.49
HIGH (1Y)
$821.11
LOW (24H)
$721.01
HIGH (24H)
$750.00
VOLUME (24H)
$104.78K
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $732.87 | |
1 Week | $750.31 | |
1 Month | $790.00 | |
1 Year | $634.14 |